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Prostaglandin-induced cervical remodelling in
humans in the first trimester is associated with
increased expression of specific tight junction,
but not gap junction proteins
Vidita V Ghulé1, Colin Gray2, Andrea Galimberti1 and Dilly OC Anumba1,3*
Abstract
Background: Prostaglandins (PG) are widely employed to induce cervical remodelling (CR) in pregnancy. However,
the underlying molecular mechanisms are not fully elucidated. Tight junctions (TJ) and gap junctions (GJ) regulate
paracellular and intercellular solute transport respectively but their role in the process of CR remains unexplored.
We hypothesized that the synthetic prostaglandin E1 analogue Misoprostol (M), widely used in clinical practice to
induce CR, may alter TJ and GJ expression as part of the changes in the extracellular matrix (ECM) associated with
remodelling. We investigated the effects of Misoprostol exposure on the expression of cervical TJ (claudins 1, 2, 4,
5, 7 and occludin) and GJ (connexins 43, 30 and 26) in the 1st trimester.
Methods: Cervical biopsies were obtained from pregnant women and comparisons of TJ and GJ protein
expression (by western blotting) and immunolocalisation (laser scanning confocal microscopy) made between
those who were administered vaginal Misoprostol (n = 10) and those who were not (n = 5).
Results: We found that Misoprostol-treated tissue (M+) had higher expression of Claudins 1,2,4,7 and occludin (p <
0.05) than untreated (M-) tissue. Expression levels of Claudins 1, 2 and 4 were positively correlated to interval from
Misoprostol treatment to biopsy, whilst occludin was negatively correlated. Misoprostol-treated cervical tissue
demonstrated more endothelial claudin-5 and occludin, whilst expression of GJs were unchanged.
Conclusion: Our observations suggest, for the first time, that increased expression of tight junction proteins may
be one of the mechanisms by which Misoprostol induces CR in humans. Further studies are needed to explore if
TJ proteins may be therapeutic targets to alter timing of CR in clinical practice.
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Background
The mechanisms by which the rigid tubular cervix soft-
ens, thins out and dilates (cervical remodelling, CR) dur-
ing pregnancy and before parturition are not fully
understood. Cervical remodelling is pivotal to the clini-
cal course and outcome of labour. Thus, understanding
the underlying molecular mechanisms of the process
may facilitate the prediction, prevention, or initiation of
labour in clinical practice.
Connective tissue predominates the cervix and under-
goes most of the remodelling of that organ. Although find-
ings vary with experimental models and species, CR is
associated with increased stromal hydration [1], disorgani-
zation of collagen bundles [2,3] and altered concentrations
of hyaluronic acid and dermatan sulphate [4]. During the
final stages of CR, there is increased nitric oxide synthesis
[5], with extravasation of leucocytes [6] and activated
fibroblasts [7]. A role for the epithelium during CR is sug-
gested by its expression of cyclo-oxygenase (COX)-2,
interleukin-8 (IL-8), glucocorticoid receptors [7-9] and
aquaporin channels [10].
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Prostaglandins (PGs) are widely used to ripen the
pregnant cervix. Easier mechanical dilation of the softer
‘PG-primed’ cervix has significantly reduced operative
morbidity associated with surgical termination of preg-
nancy (STOP) [11-13]. Misoprostol, a synthetic 15-
deoxy 16-hydroxy 16-methyl analogue of natural PG-E1
has been the drug of choice due to its effectiveness, low
cost and minimal side effects at a dose of 400 micro-
grams (μg) for 3 hours [11,14]. Human cervical biopsy
studies in 1st trimester suggest that exogenous PG
induces CR by causing disorganization of collagen, vaso-
dilatation, increasing stromal leukocytes, and stimulating
the release of pro-inflammatory cytokines [6,15,16].
However the mechanisms by which vaginally adminis-
tered PG induces these changes in the extracellular
matrix are not fully established.
TJs are sites of intercellular contact in the most apical
regions of the lateral membranes of epithelial and
endothelial cells, and regulate paracellular water and
solute transport. TJs are composed of cytoplasmic scaf-
folding proteins (zona occludens) and tetra-span trans-
membrane proteins such as junction adhesion molecules,
occludin and claudins [17]. Non-pregnant human cervi-
cal ectothelium, which is stratified squamous variety, has
been shown to express claudins 1, 2, 4, 7 and occludin
[18,19]. Changes in transcripts of cervical claudins 1 and
2 have been described in pregnant mice [20]. As predo-
minant regulators of paracellular water and solute trans-
port [21], it is possible that changes in functional
expression of TJs may contribute to CR. Animal studies
have shown that TJ may modulate the permeability of
cervical epithelium during pregnancy [20]. GJs are also
trans-membrane channels connecting the cytoplasm of
the adjacent cells. They facilitate free transfer of ions up
to 1 kiloDalton (kDa) [22]. Expression of Gap Junction
(GJ) proteins, namely Connexins (Cx) 43, 26 and 30 in
human cervical ectothelium has been described [23,24],
but whether they play a role in CR is unknown. It has
been postulated that tissue specific co-expression of var-
ious GJ and TJ proteins, by virtue of their selective per-
meability, may regulate tissue adaptation to various
physiological needs [22].
We hypothesized that the PGE1 analogue Misoprostol
may alter cervical TJ, and perhaps GJ expression, as part
of the process of CR in a time-dependent fashion.
Methods
Two 3 × 3 × 10 mm biopsies were collected trans-vagin-
ally from the anterior lip of the ectocervix from fifteen
women prior to STOP under general anaesthetic between
9 and 11 (mean = 10.4) weeks of viable gestations not
known to have fetal malformations with Trischler’s punch
biopsy forceps by a single trained researcher (VG). Ten
women received 400 micrograms vaginal Misoprostol (M)
with mean interval from treatment to biopsy of 95 min
(range 50-140 min) while 5 women did not by choice. The
mean ages of the treated and un-treated groups were 24.5
years (range 19-34) and 27 years (range 23-32) respec-
tively. The North Sheffield research ethics committee
approved this study (ref-08/H1310/35). All women gave
written informed consent. Inclusion criteria were age
between 18-45 years, previous vaginal delivery, and viable
singleton pregnancy less than 12 weeks. Women with a
history of previous cervical surgery, abnormal cervical
smears, vaginal bleeding or cervico-vaginal infections
within one week of the biopsy were excluded. We studied
only parous women in order to: a) achieve some degree of
homogeneity in the study groups, and b) ensure that
normal cervical function and compliance had been
demonstrated by previous successful vaginal delivery.
Furthermore, all nulliparous women are given Misoprostol
prior to STOP to facilitate surgical dilatation and would
have been unsuitable for our studies since we also wanted
to investigate cervical tissue not pre-treated with
Misoprostol. All samples were studied by both Western
blotting (WB) and Immunofluorescence (IF) and represen-
tative images and blots have been shown in the figures.
Western blot analysis
The tissue was homogenized in 1 ml of ice cold RIPA
(Radio-Immuno-Precipitation-Assay) buffer [1 M Tris
hydrochloride (pH 7.4), 150 mM sodium chloride, 500
mM Ethylenediamine tetra-acetic acid with protease and
phosphatase inhibitors (1 μl/ml each of Aprotinin, Leu-
peptin, Pepstatin, dithiothreitol)]; Phenylmethylsulfonyl-
fluoride 10 μL/ml and sodium fluoride 5 μL/ml-(Roche
Diagnostics, Germany) and detergents [Triton-X100-1
μl/ml, 10% Sodium Dodecyl sulphate (SDS)-10 μl/ml and
sodium deoxycholate-25 μl/ml]. The supernatant was
obtained by centrifugation at 15000 g for 20 min at 4°C
and total protein estimated by Nano-Drop™ 1000 spec-
trophotometer (Thermo Scientific, UK) at absorbance
280 nm. Samples were prepared by adding an equal
volume of SDS loading buffer [final volume of 48 ml:
6.0 ml 5 mM Tris (pH 6.8), 4.8 ml 100% (v/v) glycerol,
9.6 ml 10%SDS (v/v), 2.4 ml beta-mercaptoethanol,
1.2 ml 0.5% (w/v) bromophenol blue and 24 ml MQ
water] to the homogenate. 100 μg of crude protein was
loaded in 12.5% polyacrylamide gels. SDS PAGE was car-
ried out in 1XSDS buffer (25 mM Tris, 192 mM Glycine,
0.1% SDS) at 75 V over 2 hrs in the Mini-PROTEAN
tetra cell (Bio-Rad, UK). Following wet transfer on PVDF
membrane (Millipore, USA) at 100 V for 75 min at 4°C,
the blots were blocked in 5% non-fat milk in 1XPBS at
room temperature (RT) for 1 hour followed by overnight
incubation with primary antibodies (Zymed Labs, USA)
at 4°C. Polyclonal rabbit primary antibodies were used at
1:1000 dilutions for connexin-43(#71-0700), connexin-30
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(#71-2200), occludin (#71-1500), claudins 1 and 7 (#51-
9000 and 34-9100). Monoclonal mouse primary antibo-
dies were used for Connexin-26 (#33-5800), claudins 2, 4
and 5 (#32-5600, #32-9400, and 35-2500 respectively) at
1 in 1000 dilutions. The next day, blots were washed in
1xTBS-T (0.05% v/v) before incubation with HRP-conju-
gated goat anti mouse or anti rabbit secondary antibodies
at RT for 45 min at 1:10,000 dilution (#115-035-146,
#111-035-144; Jackson ImmunoResearch Labs, INC,
USA). After three 10 min washes in 1XTBS-T, the blots
were immersed in Immobilon Western Chemiluminis-
cent Horse-Radish Peroxidase substrate solution (Milli-
pore, USA) prepared as per manufacturer’s instructions.
Images were captured using G-box (Syngene, UK) with
Genesnap software at 1, 5 and 10 minutes. Semi-quantifi-
cation was done using Gene tools gel documentation and
analysis software (Syngene, UK). Having first confirmed
that the expression of G-beta was unaffected in Miso-
prostol treated and untreated pregnant cervical tissue by
semi-quantification using western blotting, G-beta was
used as loading control. Human myometrial and placen-
tal tissues served as positive controls for GJ and TJ pro-
teins respectively [25,26] and the same protocols were
followed as for the cervical tissue.
Laser scanning confocal microscopy (LSCM)
Localization of the matrix proteins was studied by
LSCM imaging by sequential dual indirect immuno-
fluorescence with Cyanine-3 (Cy-3) and Fluorescin iso-
thiocynate-C (FIT-C) conjugated secondary antibodies.
10 μm thick frozen sections were fixed in 100% ice cold
acetone for 10 min. After two 5 min washes, blocking of
non-specific antigen sites was carried out in 5% goat
normal serum (GNS) and 5% bovine serum albumin
(BSA) in 1X PBS at RT for 1 hour. Overnight incuba-
tions in primary antibodies (all from Zymed labs, USA)
were carried out at 4°C as mentioned in section on wes-
tern blotting: connexin-43, claudins-2, 4, and 5 at 1:100
dilution; 1:200 dilution for connexin-30, occludin, clau-
dins 1 and 7 with 1:60 dilution for connexin-26. Next
day, incubations with Cy-3 conjugated goat anti-rabbit
antibody (#111-165-144, Jackson ImmunoResearch,
USA) and FIT-C conjugated goat anti-mouse secondary
antibody (#115-095-146) were carried out sequentially at
1:400 in dark at RT for 45 min each. Negative controls
were incubated in either mouse or rabbit isotype control
IgG (#08-6599, #08-6199; Zymed Labs, USA) instead of
primary antibodies. Positive controls were treated in
exactly similar way throughout. After three 10 min
washes in 1X TBS-T, sections were air dried before
mounting in a drop of Vectashield hard-set mounting
medium with DAPI (Vector Labs, USA). Images were
acquired with an LSM 510 NLO inverted microscope
(Carl Zeiss, Germany) using 20X/0.8 and 40X/1.3 oil
immersion objectives. Images were acquired sequentially
to eliminate the risk of cross talk. FIT-C was examined
using 488 nm Argon laser excitation, a dual band 488/
543 dichroic mirror, a NFT545 beam splitter and
BP500-530 nm IR emission filter. Cy3 was examined
using a 543 nm Helium Neon laser, a dual band 488/
543 dichroic mirror, a NFT545 beam splitter and
BP565-615 nm IR emission filter. Images of DAPI stain-
ing were taken using multiphoton laser tuned to 740
nm a KP650 dichroic mirror and 390-465 nm emission
filter. Unstained and control specimens were examined
using the same microscope settings as those used to
acquire images from the antibody labeled tissue sections.
Statistical analysis
Data were analysed using SPSS version 18 (Statistical
Package for Social Science, Inc., Chicago, IL) employing
descriptive statistics, analysis of variance, T-tests, Mann-
Whitney U tests and tests of correlation as were appropri-
ate following assessment of normality of distribution (Sha-
piro-Wilk’s test) and equality of variance between groups
(the Levene’s test), and corrections for multiple compari-
sons by post hoc analysis. Data was considered significant
for p values less than 0.05. LSCM data was not used for
quantification.
Results
All patient samples were studied by both techniques-
immune fluorescence analysis and western blotting. The
patterns described were seen in all samples and the con-
focal images and immunoblots shown are representative
of the entire samples.
Effect of Misoprostol on expression of tight junction
proteins
There was significantly increased expressions of claudins
1, 2, 4 and 7 (Figure 1a-d) and occludin (Figure 2b, c) in
Misoprostol-treated (M+) compared to the untreated
(M-) cervix. For occludin, in addition to the 65 kDa
bands, we found consistent bands at 50 kDa and
between 37-40 kDa in both groups in all specimens stu-
died. Misoprostol-treated tissue demonstrated increased
expression of all these bands significantly (p < 0.01 for
50 & 65 kDa and p < 0.05 for 37-40 kDa) (Figure 2b).
With increasing time interval from PG treatment to
obtaining the biopsy, occludin expression declined (r =
-09 P = 0.016), claudins-2 and -4 increased (r = 0.98, P
= 0.0001 and r = 0.86, P = 0.014 respectively) whilst
Claudin-7 (r = 0.70, P = 0.08) and Claudin-1 (r = -0.07,
P = 0.88) expressions did not change significantly. Sig-
nificant correlations with time of administration of Mis-
oprostol are illustrated in Figure 2a.
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Effects of misoprostol on localisation patterns of tight
and gap junction proteins
Subtle changes in immunolocalisation of TJ in cervical
epithelium were observed with Misoprostol treatment:
occludin which was mainly expressed in the basal layer of
the untreated cervix (Figure 3a-red) appeared to localise
more in the intermediate and more superficial layers of
tissue treated with Misoprostol (Figure 3b-red). Whereas
in the untreated cervix, occludin and claudin-2 were
expressed only in the basal layer (Figure 3a-Overlay),
Misoprostol treated tissue demonstrated expression of
claudin-2 in the intermediate layer (Figure 3b-green),
shifting the co-localisation of both proteins to basal and
intermediate layers (Figure 3b overlay). Claudin-4 was
expressed mainly in nuclei throughout the ectothelium in
the untreated cervix (Figure 3c-green), whilst Misopros-
tol treatment induced expression in the cytoplasmic
membranes (Figure 3d, f). Interestingly, claudins 1 and 4
exhibited nuclear and cytoplasmic membrane co-expres-
sion in Misoprostol-treated group (Figure 3f) which was
absent in the untreated group (Figure 3e). Whilst Clau-
din-1 was expressed mainly in nuclei throughout the
ectothelium in the untreated cervix (Figure 3e-red); PG-
treated tissue showed both nuclear and cytoplasmic
membrane staining, the latter giving a lattice pattern
(Figure 3f). Claudin-7 was expressed in a diffuse lattice
pattern in basal and intermediate layers in the untreated
cervix (Figure 3c-red), whereas with Misoprostol
Figure 1 Comparison of expression levels of claudins- 1 (1A), 2 (1B), 4 (1C) and 7(1D) in Misoprostol treated (M+) (samples 1+ to 7+) versus
untreated (M-) (samples 1- to 5-) cervix. Representative immunoblots in the top panels whilst box plots, lower panel, represent mean (SE) relative
optical densities (ROD) for all studied tissues: M+ (n = 10) vs. M- (n = 5). Block arrows showing Gbeta as internal loading control at 35 kDa. C-positive
control in the first lane. C-1 = claudin-1; C-2 = claudin-2; C-4 = claudin-4; C-7 = claudin-7. ROD- relative optical density in Arbitrary Units (AU).
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treatment, expression was mainly in the intermediate
layer (Figure 3d-red).
Vascular expression of claudin-5 and occludin
Claudin-5 was selectively localized to the vascular
endothelium (Figure 4a-green) whilst occludin was
expressed in the vascular smooth muscle in addition to
the squamous ectothelium in the human cervix (Figure
4a-red). PG treatment appeared to increase expression
and also cause co-localization of claudin-5 and occludin
in the vascular endothelium (Figure 4b-overlay).
Furthermore, the blood vessels in the PG-treated cervix
Figure 2 a: Scatter plot and trend-lines demonstrating positive correlation of claudin-2 (r 0.98, P < 0.001) and claudin-4 (r 0.86, P < 0.05)
expressions, and negative correlation of occludin expression (r -0.90, P < 0.05), with time from Misoprostol treatment (M+) to cervical biopsy
in minutes. Occludin relative optical density (ROD) in arbitrary units (AU) is plotted on a secondary y-axis (right) whilst the ROD for claudin-2 and claudin-
4 are shown on the primary y-axis (left). b: Representative immunoblots depicting significant increase in all isoforms of occludin with Misoprostol
treatment (M+) compared to the untreated (M-) cervix in the first trimester of pregnancy. Arrow at G-beta as internal loading control. C-positive control. c:
Box plots comparing mean (SE) relative optical densities (ROD) of different isoforms of occludin for all studied tissues: Misoprostol treated (M+, n = 10) vs.
Untreated (M-, n = 5). LMW-low molecular weight at 37-40 kDa; HMW- high molecular weight at 50 & 65 kDa; overall- LMW and HMW combined.
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Figure 3 Representative confocal photomicrographs comparing localization patterns of claudins-1 (C1), -2(C2), -4(C4) and -7(C7) and
occludin (Ocld) in Misoprostol treated (M+, right panel) and untreated (M-, left panel) cervix. The FIT-c (green) and Cyanine-3 (Cy-3-red)
labelled secondary antibodies were used; DAPI (blue) for nuclear staining with overlays of red, green and blue (RGB) channels. In the untreated
cervix, occludin (red) shifted to intermediate and more superficial layers (3B-red). In the untreated cervix, occludin (3A-red) and claudin-2 (3A
green) were expressed in basal layers only (3A-overaly) but following Misoprostol treatment, de novo expression of claudin-2 (3B-green) in the
intermediate layer resulted in both now localizing in the basal and intermediate layers (3B-overlay). Compared to diffuse lattice pattern in basal
to intermediate layers in the untreated cervix (3C red), Misoprostol induced expression of claudin-7(3D red) in basal and intermediate layers.
Claudin-4 was expressed mainly in the nuclei throughout the ectothelium (3C green) in the untreated cervix, with de novo cytoplasmic
expression in Misoprostol-treated tissue (3D & 3F green). Claudins 1 and 4 exhibit nuclear and plasma membrane expressions in Misoprostol-
treated cohort (3F). Arrows at basement membranes; S-stroma, E-epithelium. 3A- 2 × 2 tile; × 20air objective. NA-0.8, Bar = 8 μm.
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Figure 4 Effect of Misoprostol treatment on localization of vascular endothelial tight junctions occludin and claudin-5 . a and b:
Representative confocal images comparing expressions of claudin-5 (C-5) (green) and occludin (red) in the cervical vascular endothelium without
(4A) and after PG treatment (4B). In the neat (PG-) cervix, C-5 was selectively localized in the endothelium (4A-green) whilst occludin (Ocld) was
mainly expressed in the smooth muscle (4A-red). Treatment with misoprostol (M+) induced expressions of both C-5 and occludin (4B) compared
to the untreated (M-) cervix (4A). Also, de novo endothelial expression of occludin was seen with PG treatment (4B red vs. 4A red; overlays 4A
vs. 4B). × 40, oil immersion; NA = 1.3; Bar 8 μm. c-d: Representative confocal photomicrographs showing larger calibre of blood vessels in the PG
treated (PG+) compared to the untreated (PG-) cervix (Figure 4D Vs. 4C) ×20 air objective, NA 0.8, Bar = 8 μm. Extreme right panels depicting H
& E stained histological section of cervical stroma in the M+ and M- tissues. E: Positive and negative controls for occludin and claudin-5.
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were consistently larger compared to the un-treated cer-
vix (Figure 4d vs. 4c). Our attempts at immuno-blotting
of claudin-5 were unsuccessful.
Effect of Misoprostol treatment on expression of Gap
junction proteins
Misoprostol treatment was not associated with signifi-
cantly altered expression of any of the GJ proteins stu-
died: a trend towards increased expression of Cx-30 in
Misoprostol-treated tissue did not attain statistical sig-
nificance (Figure 5a and 5b). Furthermore, immune-
localisation patterns of these GJs in human cervical
ectothelium did not differ with Misoprostol treatment
(Figure 5c and 5d).
Discussion
This study reports, for the first time, that cervical remo-
deling induced by Misoprostol in the first trimester is
associated with increased expression of claudins 1, 2, 4,
7 and occludin, as well as increased vascular endothelial
expression of claudin-5 with concomitant vasodilatation.
Our findings support the hypothesis that cervical TJs
may play an important role in Misoprostol-induced cer-
vical remodelling. Taken together with recent reports
that PG-induced cervical remodelling involves increased
stromal leukocytes and cytokines [27] which can regu-
late paracellular permeability [28], our observations
strongly suggest that altered TJ expression and function
may modulate cervical ECM remodeling by altering
paracellular permeability.
We found a positive correlation between expression
levels of claudins 2 and 4 and the time interval from Mis-
oprostol treatment to biopsy, further supportive of the
thesis that Misoprostol administration and TJ expression
are linked, perhaps causally. It is tempting to speculate
that this temporal change in expression levels may be
attributable to changes associated with the signaling cas-
cade involved in cervical remodelling. Clinical trials have
shown that the efficacy of vaginal Misoprostol for cervical
priming is both dose- and time-dependent [11,14], and is
related to time to attain peak plasma concentrations (70-
80 min after vaginal administration) [29]. It is plausible
that the increase in cervical epithelial TJ expression in
response to Misoprostol treatment serves to promote
trans-epithelial permeability, increasing local tissue deliv-
ery of Misoprostol and its plasma concentrations. Further
studies are required to confirm this, and whether TJs play
a more direct modulatory role in CR.
Misoprostol significantly increased expression of all the
forms of occludin: we consistently found occludin bands
at 65 kDa, 50 kDa and between 37-40 kDa in all studied
specimens. Previous in vitro studies have attributed such
bands between 62 to 82 kDa on SDS-PAGE to phos-
phorylated forms of occludin [30-32]. Whether post-
translational modification of occludin by phosphorylation
is a mechanism by which Misoprostol treatment alters
trans-epithelial resistance and permeability during cervi-
cal remodelling is unclear. An alternative hypothesis has
been that the 50 kDa and 37-40 kDa isoforms of occludin
may reflect rapid occludin turnover during pregnancy
[33]. Such breakdown turnover to the 50 kDa isoform
has been shown to reduce TJ resistance of cervical
epithelium [34], suggesting that low molecular weight
forms of occludin, being low resistance pathways, may
increase epithelial layer permeability leading to increased
stromal hydration. The significance of the inverse corre-
lation of cervical occludin with time of Misoprostol
administration is unclear. One explanation is that the
maximal effect of Misoprostol on occludin expression is
achieved very rapidly compared to claudins 2 and 4, wan-
ing thereafter in a time-dependent fashion.
Claudin-5 was selectively localized to the vascular
endothelium whilst occludin was expressed mainly in the
vascular smooth muscle. Their increased expression and
mediation of trans-endothelial migration of T lympho-
cytes and macrophages [35], together with the reported
recruitment by PG of chemotactic leukocytes [16] and
mast cells [6], are strongly supportive of important roles
for TJ in the regulation of vascular permeability
[15,27,36] in the ECM during Misoprostol-induced CR.
Whether Misoprostol-induced nuclear membrane
expression of claudins 1 and 4 (Figure 3f) observed by us
could imply increased transcription or interaction with
nuclear PGE1-4 receptors as suggested by others [37]
needs further investigation. Misoprostol did not signifi-
cantly affect the expression of gap junction proteins, sug-
gesting that they are unlikely to play key roles in
Misoprostol-induced CR.
The interpretation of our observations should be subject
to some caveats. Firstly, we have not demonstrated any
significant effect of misoprostol on cervical GJ expression
in the limited number of tissue samples studied. However
ethical constraints precluded taking further biopsy samples
once significant effects had already been demonstrated for
TJ expression. We would have needed more than two
hundred cervical biopsies to demonstrate a 20% difference
in the expression of connexins- 43 and 26 between Miso-
prostol-treated and non-treated cervix with 80% power at
the 95% confidence level. It is plausible that a role for GJs
in cervical ripening was not detectable by our limited sam-
ple sizes and assay techniques, or that GJs may modulate
remodelling processes induced by other synthetic or natu-
rally-occurring prostagladin analogues which we have not
studied. Secondly, the heterogeneity of expression of dif-
ferent TJs (seen as varying band intensities in western
blotting- Figures 1 and 2b) in the Misoprostol-treated
group could be partly due to the varied duration of expo-
sure to Misoprostol, as well as individual variations in
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Figure 5 Effect of prostaglandin treatment on expression of gap junction proteins-connexins 43, 30 and 26. A: Representative
immunoblots of connexins 43, 30 and 26 in untreated (M-) and Misoprostol treated (M+) cervix in first trimester. C-positive control. B: Graphical
representation comparing expressions of connexin- 43 (CX-43), connexin-30 (CX-30) and connexin-26 (CX-26) in Misoprostol treated (M+, n = 10)
versus untreated (M-, n = 5) cervix on Western blotting. The expression of the studied connexions did not differ between Misoprostol-treated
and untreated tissue. C and D: Representative confocal photomicrographs depicting no change in localisation patterns of connexins 30 and 26
in untreated (M-) (Figure 5C) versus Misoprostol treated (M+) (Figure 5D) cervix. Bottom row showing positive controls (myometrium) and
negative controls (cervical tissue) for connexins 26 and 30. DAPI- nuclear staining. e- epithelium, s-stroma. Arrows at basement membranes. ×20
air objective, NA 0.8, Bar = 8 μm.
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subject responses [27]. Despite these considerations we
still observed significant differences between Misoprostol-
treated and untreated cervix, strongly suggesting a true
effect of Misoprostol on cervical expression of some TJ
proteins. It was not practicable to fix the time interval
between administration of Misoprostol and the cervical
biopsy as this depended on a highly variable transit time
between the wards, the operating theatres and the admin-
istration of anaesthetic for the clinical procedure. Record-
ing the variation in time to biopsy from Misoprostol
administration enabled us to serendipitously observe a
time-dependent change in expression of some of the TJ
proteins studied.
Conclusion
We report for the first time that cervical tissue treated
with Misoprostol, a synthetic PGE1 analogue, demon-
strated increased expression of specific epithelial and
endothelial TJ proteins in the pregnant human cervix
in a time-dependent fashion. This suggests that signals
that regulate trans-epithelial transport in the cervix
may act by regulating TJ mediated paracellular perme-
ability, highlighting a potential role for these matrix
proteins in modulating cervical remodelling induced by
Misoprostol. Further studies are needed to clarify the
mechanism of this interaction during tissue remodel-
ling, and to determine whether our observations in
first trimester are mirrored during spontaneous ripen-
ing at term. These studies are necessary as they may
clarify the mechanism of failed initiation of labour
using PG analogues, as well as uncover new therapeu-
tic targets.
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